CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 CongressAccesswire • 09/13/24
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine ProgramAccesswire • 09/12/24
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 CongressAccesswire • 09/09/24
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business UpdateAccesswire • 08/15/24
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected GlioblastomaAccesswire • 08/15/24
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory BoardAccesswire • 08/15/24
CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 08/08/24
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTechAccesswire • 07/11/24
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial OfficerBusiness Wire • 07/11/24
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccinesMarket Watch • 07/03/24
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline OpportunitiesAccesswire • 07/03/24
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business UpdateAccesswire • 04/24/24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSKAccesswire • 04/24/24
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024Accesswire • 04/18/24